Auris Medical Holding AG (NASDAQ:EARS) was up 4.6% on Monday . The company traded as high as $4.00 and last traded at $3.83, with a volume of 115,199 shares changing hands. The stock had previously closed at $3.66.

A number of equities research analysts recently weighed in on EARS shares. Zacks Investment Research upgraded shares of Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a report on Tuesday, July 12th. Jefferies Group reiterated a “buy” rating on shares of Auris Medical Holding AG in a report on Friday, June 10th. Finally, Leerink Swann reiterated a “buy” rating on shares of Auris Medical Holding AG in a report on Thursday, May 12th.

The company’s 50 day moving average is $3.84 and its 200-day moving average is $4.08. The firm’s market capitalization is $129.42 million.

Auris Medical Holding AG (NASDAQ:EARS) last released its earnings results on Wednesday, May 11th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.04. During the same period last year, the firm earned ($0.28) EPS. Equities research analysts expect that Auris Medical Holding AG will post ($1.01) earnings per share for the current year.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.